Today, we’re diving into what GLP‑1 medications—like Ozempic, Wegovy, Mounjaro, and Zepbound—are really doing for fat‑loss and overall well‑being, what science says, and how generics coming soon could shift access for many.
1. Better Understanding GLP‑1, GIP & Glucagon Receptor Effects
First let’s talk about the science that fuels these medications—and why it’s so important to your fat‑loss journey.
-
GLP‑1 (Glucagon‑like peptide‑1): A hormone released from the gut after eating. It boosts insulin output when glucose is high, slows stomach emptying, reduces glucagon (which typically raises blood sugar), and signals your brain to slow down food intake and feel fuller faster.
-
GIP (Glucose‑dependent insulinotropic polypeptide): Another hormone that encourages insulin release after a meal and helps clear fats from circulation.
-
Glucagon receptor activation: Glucagon normally raises blood sugar by prompting the liver to make more glucose. But in the right context, a low dose boosts metabolism, encouraging fat breakdown and calorie burn—even while helping to curb appetite when combined with GLP‑1/GIP signals.
Now imagine a single medication that targets just one receptor—that’s powerful. But what if you could engage two or even three? That’s where the latest weight‑loss drugs enter the ring. For the below – agonist = activates the receptor.
-
GLP‑1 agonists (like Ozempic, Wegovy) primarily tackle appetite and improve blood sugar.
-
Dual agonists (like Mounjaro, Zepbound) harness both GLP‑1 + GIP—ramping up insulin support and fat metabolism.
-
Triple agonists (like retatrutide – as of the time of this blog post this drug is not commercially available yet) GLP-1 + GIP + glucagon receptor activation = turning down the volume on hunger and turning up the flame on fat burning.
2. The Heavy‑Hitters: Ozempic, Wegovy, Mounjaro & Zepbound
Ozempic & Wegovy
Both contain semaglutide, a GLP‑1 receptor agonist. Ozempic is prescribed for type 2 diabetes; Wegovy is its cousin—specifically labeled for weight‑loss and long‑term weight maintenance.
Mounjaro & Zepbound
These are built on tirzepatide, a dual GIP/GLP‑1 agonist (fancier, combo‑style hormone mimicry). Mounjaro helps with diabetes control, while Zepbound is approved for weight management—and even obstructive sleep apnea in some cases.
Upcoming: Retatrutide
Retatrutide will be the first triple agonist, consistent of GLP‑1, GIP, and glucagon receptor effects. As mentioned earlier, this not only helps curb hunge but it also boosts how many calories your body burns.
3. The Patent Game-Changer in Canada
In Canada, Novo Nordisk (a company that makes semaglutide) lost its semaglutide patent because of a missed ~$250 maintenance fee—a tiny oversight with huge consequences. That lapse has already opened the door for generic semaglutide in Canada, and even inspired talk of import programs that could benefit U.S. patients.
Canada’s generic drug maker Sandoz is even positioning to slash prices by up to 70% once generics begin, potentially bringing monthly costs down to ~$40‑50 CAD instead of $200‑400 CAD.
This unforeseen development means these tools might soon be more affordable and accessible.
4. The Balance: A Dietitian’s Informed, Honest Approach
As an RD, here’s what I want you to know:
- These weight loss medications are powerful tools—especially for those struggling with stubborn weight, metabolic health, or who struggle with “food noise” despite eating healthy.
- These meds should not be thought of as magic bullets. They should be used on top of good habits – nutrition, exercise, sleep, etc.
- With any drug, there is always the possibility of side effects—namely nausea, constipation, and fatigue. I’ve had clients that have started the medications but decided to stop becuase the side effects were just not worth it (I’ve also had clients that have had no side effects).
- Generics are coming —and that will reshape access and equity in healthcare for many.
- Retatrutide might be a game‑changer. Early research is showing that is may spare muscle while burning fat—and even improve liver health; but, safety data is still emerging.
FYI: Who Makes These Drugs—and Why It Matters
-
Novo Nordisk (company based out of Denmark) produces Ozempic and Wegovy. They poured billions into R&D, aiming to recoup costs before generics arrive—but the Canadian oversight may upend that plan.
-
Eli Lilly (company based out of United States) makes Mounjaro and Zepbound (and upcoming Retatrutide). Their CEO points to the $3 billion and 15 years needed to develop these drugs to justify pricing—but they also face the reality of generics challenging affordability.
There’s a tension here: innovation needs rewards, but public health demands access. That’s why generics—when we can safely use them—can be a turning point from hype to real health equity.